Protocol XL184-021: A phase 1 trial of combination therapy comprised of cabozantinib and atezolizumab in patients with advanced or metastatic solid tumors.
The trial is available to patients diagnosed with the following tumor types:
Non-small Cell Lung Cancer (Non-squamous)
Castration-Resistant Prostate Cancer (High Risk, Adenocarcinoma).
For more information please contact the clinical research department: 631-675-5075